

TOPICAL TIMOLOL EYE DROP SOLUTION FOR THE TREATMENT OF FISSURES IN PATIENTS WITH HAND DERMATITIS

Darsim Mohammed Abdalla ^a



Submitted: 17/11/2021; Accepted: 25/2/2022; Published: 21/6/2022

ABSTRACT

Background

Some patients with chronic hand dermatitis may complain of painful and itchy fissures; in some cases, the fissures are reluctant to conventional therapies of hand dermatitis.

Objectives

To evaluate the efficacy and safety of topical timolol eye drop 0.05% solution for the treatment of fissures in patients with hand dermatitis.

Patients and Methods

In this therapeutic trial, twenty-two cases with chronic hand dermatitis whose hand fissures are unresponsive to conventional therapies are treated with a single daily application of topical timolol eye drop 0.05% solution on the fissures for three weeks; those with complete disappearance of the fissures and symptoms are regarded as complete response, those with a decrease in size and number of fissures with partial or no improvement of symptoms are regarded as a partial response, and those with no change in size and number of fissures with no improvement in symptoms are regarded as no response, search of any side effect done.

Results

The age of the patients ranged from 16-39 years, and the majority were females. Eleven patients (50%) showed complete response, eight patients (36.4%) had a partial response, and three patients (13.6%) had no response. Patients with a single fissure had a statistically significant better response than those with multiple fissures. No, local or systemic side effects were recorded.

Conclusion

Topical timolol solution is an effective and safe choice for treating fissures in patients with hand dermatitis.

Keywords: *Timolol eye drop solution, Hand dermatitis, fissures.*

^a College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.
Correspondence: darsim.abdalla@univsul.edu.iq

INTRODUCTION

Hand eczema, or dermatitis of the hand, is an inflammatory condition of the skin of the hands; the prevalence in the general population was up to 14%⁽¹⁾. Clinical manifestations include erythema, edema, scaling, hyperkeratosis, vesiculation, fissuring, papules and plaques⁽²⁾. Chronic hand eczema refers to the eczematous process involving the hands that last more than three months or relapses twice or more per year despite adequate treatment and treatment adherence⁽³⁾. The etiologies are complicated and involve interaction among both extrinsic, including irritants and contact allergens, and intrinsic factors, such as predilection to atopy or filaggrin gene mutation⁽⁴⁾.

Since chronic hand eczema is refractory to the treatments, various treatment options have been studied to demonstrate their responses. Along with moisturizers and skin protection, potent topical steroids, tacrolimus and in refractory cases, systemic immunosuppressive agents, acitretin, and psoraline plus ultraviolet light A (PUVA) are beneficial. However, fissures and erosions are resistant to therapy and troublesome to patients due to associated pain and discomfort⁽⁵⁾.

Beta-adrenergic receptors are present on cells in multiple organ systems, including the skin. Within the skin, receptors are present on keratinocytes, fibroblasts, and melanocytes, and they may have a role in the pathophysiology of dermatologic conditions, including atopic eczema, psoriasis, and vitiligo⁽⁶⁾. Beta-adrenergic blockade by topical timolol maleate has been proposed as a therapeutic agent for non-healing wounds of various etiologies with good outcomes⁽⁷⁾; it also accelerates the recovery of the barrier function of the damaged skin⁽⁸⁾.

Beta 2-adrenergic receptors (B2AR) play a role in cutaneous homeostasis; B2AR antagonists, e.g. timolol, increase ERK (extracellular signal-regulated kinases) phosphorylation, keratinocyte migration and thus accelerate skin wound re-epithelialization. In acute partial-thickness donor site wounds, B2AR antagonists have been reported to promote wound healing. One potential mechanism is via keratinocyte migration, which occurs by the facilitation of chemotaxis, the polarization of cells, and activation of extracellular signal-related kinases essential in the signalling of promigratory pathways. The B2AR activation inhibits keratinocyte migration by activating the serine/threonine phosphatase 2A, which down-regulates phosphorylation of extracellular signal-related kinases

necessary for migration. Therefore, B2AR antagonists prevent the phosphorylation of phosphatase 2A and have the downstream effect of extracellular signal-related kinase promotion, including a promigratory pathway in keratinocytes⁽⁹⁾.

Keratinocyte migration also occurs by galvanotaxis, in which cells migrate in response to electric stimuli. For example, keratinocytes can be stimulated to migrate by forming electrical poles and applying electrical fields⁽⁹⁾. The B2AR antagonists improve the ability of keratinocytes to respond to such migratory cues. In contrast, the B2AR agonists decrease keratinocytes' ability to respond, further implicating the use of topical timolol for recalcitrant wounds⁽¹⁰⁾.

The aim of this study is evaluate the efficacy and safety of timolol eye drop 0.05% solution for the treatment of fissures in patients with hand dermatitis

MATERIALS AND METHODS

A therapeutic trial was conducted in a private dermatology clinic in Sulaimani city-Iraq, from January 2021 to July 2021, in which topical timolol eye drop 0.05% solution was used to manage fissures in patients with chronic hand dermatitis. Twenty-two patients have chronic hand dermatitis with fissures that do not respond to conventional therapies for hand dermatitis of either sex or at any age.

- Patients meeting the following criteria are excluded from the study:
- Patients used topical or systemic therapy for their hand dermatitis during the last six weeks before participating in this study.
- Patients with bronchial asthma or severe chronic obstructive pulmonary disease because timolol has the potential risk of triggering bronchoconstriction.
- Patients with known heart diseases may worsen by timolol like heart block.
- History of hypersensitivity to timolol.
- Pregnant and lactating females.

Each patient's history was taken regarding age, sex, occupation, duration of the disease and the main symptoms (pain or itching).

Close examination of the hands was performed for the clinical diagnosis of their dermatitis, and the number, size and site of the fissures were recorded.

Patients are instructed to put 1-2 drops of timolol solution on the centre of the fissures at night for three weeks; photographs of the fissures are taken before starting the treatments and after three weeks.

Response to therapy is measured as follows:

-Complete response (complete re-epithelialization and disappearance of the fissures with the complete improvement of the symptoms).

-Partial response (decrease in the size and number of the fissures and no or partial improvement of symptoms, but not complete disappearance).

-No response (neither decrease in size nor number of the fissures and no improvement of symptoms).

Any local or systemic side effects were recorded.

The informed consent is taken from any patient.

Statistical analysis

Data entered into Microsoft Excel in which coding & clearing of data were done, then transferred into SPSS program version 22 (statistical package of social science) in which two approaches were used for statistical analysis (descriptive approach & analytical approach); the descriptive approach was used for finding frequencies, percentages, means and standard deviation & constructing charts and figures; while the analytical approach was used for finding associations and P-values by using Chi-square test, t-test & ANOVA Table. A p-value ≤ 0.05 is regarded as a statistically significant association between variables.

RESULTS

Demographic criteria

Participants' mean age/ year was 26.95 ± 6.67 , the minimum age was 16 years, and while maximum age was 39 years. Fifteen cases were females, and seven were males, regarding occupation; eleven cases were homemakers, five cases were workers, four were students, and two were teachers, Table 1.

Clinically

The duration of the disease ranged from 8 months to 2 years. Most patients had more than one fissure, and only six cases had a single fissure. The most common site for the fissures was fingers, two cases had fissures on the sides of the palms only, and five patients had fissures on both palms and fingers. The majority complained of pain and itching; five cases complained only from pain, and three only pruritus. The size of the fissures was not more than a few millimetres, Table 2.

Response

After three weeks of topical timolol solution use:

-Eleven patients had a complete response.

-Eight patients had a partial response, of whom five cases had both decreases in number and size of the lesions with partial improvement of symptoms. In contrast, three cases only decreased the size of the lesions with partial improvement of the symptoms.

-Three patients had no response (Table 3) and (Figures 1 and 2).

Patients with a single fissure had a statistically significantly better response than those with multiple fissures (P value=0.01). However, there was no significant difference in response regarding gender, occupation or site of fissures, Table 4.

Side effects

None of the patients had local or systemic side effects.

Table 1. Socio-demographic characteristics of patients.

| Socio-demographic characters | Frequency | Percentage |
|------------------------------|-----------|--------------|
| Gender Male | 7 | 31.8 |
| Female | 15 | 68.2 |
| Occupation Housewife | 11 | 50.0 |
| Student | 4 | 18.2 |
| Teacher | 2 | 9.1 |
| Worker | 5 | 22.7 |
| Total | 22 | 100.0 |

Table 2. Frequency & percentage of clinical characteristics of the patients.

| Variables | Frequency | Percentage |
|-----------------------------------|-----------|--------------|
| Number of fissure Multiple | 16 | 72.7 |
| Single | 6 | 27.3 |
| Site of fissure Finger | 15 | 68.2 |
| Palm & Finger | 5 | 22.7 |
| Palm | 2 | 9.1 |
| Symptoms Pain & Pruritus | 14 | 63.6 |
| Pain | 5 | 22.7 |
| Pruritus | 3 | 13.7 |
| Total | 22 | 100.0 |

Table 3. Response of the cases with fissures to topical timolol solution.

| Response | Frequency | Percentage |
|-----------------|-----------|--------------|
| Complete | 11 | 50.0 |
| Partial | 8 | 36.4 |
| No | 3 | 13.6 |
| Total | 22 | 100.0 |



Figure 1. Complete response of fissures to 3 weeks use of topical timolol solution.



Figure 2. Partial response of fissures to 3 weeks use of topical timolol solution.

Table 4. Association between some variables & response to the treatment.

| Variables | Responses (no. & %) | | | Total | P-value |
|------------------------|---------------------|------------------|------------------|-------------------|---------|
| | Complete | Partial | No | | |
| Gender: | | | | | |
| Male | 4 (36.4) | 2 (25.0) | 1 (33.3) | 7 (31.8) | 0.87 |
| Female | 7 (63.6) | 6 (75.0) | 2 (66.7) | 15 (68.2) | |
| Symptom: | | | | | |
| Pain | 2 (18.2) | 2 (25.0) | 1 (33.3) | 5 (22.7) | 0.93 |
| Pruritus | 2 (18.2) | 1 (12.5) | 0 (0.0) | 3 (13.6) | |
| Pain and Pruritus | 7 (63.6) | 5 (62.5) | 2 (66.7) | 14 (63.6) | |
| Fissure number: | | | | | |
| Single | 6 (54.5) | 0 (0.0) | 0 (0.0) | 6 (27.3) | 0.01 |
| Multiple | 5 (45.5) | 8 (100.0) | 3 (100.0) | 16 (72.7) | |
| Fissure site: | | | | | |
| Finger | 9 (81.8) | 5 (62.5) | 1 (33.3) | 15 (68.2) | 0.38 |
| Palm | 0 (0.0) | 1 (12.5) | 1 (33.3) | 2 (9.1) | |
| Palm&Finger | 2 (18.2) | 2 (25.0) | 1 (33.3) | 5 (22.7) | |
| Occupation: | | | | | |
| Student | 3 (27.3) | 1 (12.5) | 0 (0.0) | 4 (18.2) | 0.639 |
| Housewife | 4 (36.4) | 5 (62.5) | 2 (66.7) | 11 (50.0) | |
| Worker | 2 (18.2) | 2 (25.0) | 1 (33.3) | 5 (22.7) | |
| Teacher | 2 (18.2) | 0 (0.0) | 0 (0.0) | 2 (9.1) | |
| Total | 11 (100.0) | 8 (100.0) | 3 (100.0) | 22(100.00) | |

DISCUSSION

Twenty-two patients enrolled in this therapeutic trial, and their mean age was 26.95 ± 6.67 ; this finding is compatible with Fathil's study ⁽¹¹⁾, which showed that most of the cases were in the age group of 20-29 years. This may represent the age of maximum physical activity and exposure to irritant chemicals. In addition, females outnumbered males by about two folds; this result was similar to the result of Mollerup's study ⁽¹²⁾ showed that hand eczema is twice as frequent in women as in men partly because of diverse exposure patients.

In this study, we took those patients who had fissures due to chronic hand eczema, the majority with multiple fissures complaining of pain and itching and failure to respond to topical and systemic therapies used for hand dermatitis; Pawar described the use of topical timolol in 0.5% ophthalmic solution in a 45-year-old man with chronic persistent hand eczema. The patient's fissures and erosions do not respond to prior topical clobetasol propionate, topical tacrolimus, or oral methotrexate. At one week of follow-up, erosions and fissures had healed significantly. The patient was instructed to continue therapy for one month, during which there was no recurrence of fissures or erosions ⁽¹³⁾.

Based on this result and the excellent results of using topical timolol for recalcitrant wounds conducted by Liza R. Braun ⁽¹⁴⁾ and his colleagues on five cases who had recalcitrant wounds (chronic venous leg ulcer, pressure ulcer, traumatic refractory wound and mixed origin of sickle cell and venous leg ulcer), we decided to conduct this study, using topical timolol for fissures in patients with hand dermatitis.

After three weeks of daily application of topical timolol solution on the fissures, eleven patients had a complete response (complete disappearance of the fissures and symptoms), eight patients had a partial response, of whom five cases had both decreases in number and size of the lesions with partial improvement of symptoms while three cases had only decrease in size of the lesions with partial improvement of the symptoms and unfortunately three patients had no any response. We think that these good fissures' response to timolol solution may be due to the timolol's ability to increase extracellular signal-regulated kinases phosphorylation which promotes keratinocyte migration and thus accelerates skin wound re-epithelialization ⁽⁹⁾, together with the recovery of the barrier function of the damaged skin ⁽⁸⁾.

We found that there was no significant association between response to treatment with the site of fissures, sex of patients and their occupation; on the other hand, all patients with single fissure had a complete response, while half of the patients with multiple fissures had a partial response, 5 cases complete response and 3 cases had no any response, so those with single fissure better responded, which may be due to compliance of patients by applying the medication on all the fissures.

The drug was well-tolerated, and any local or systemic side effects were not recorded.

In conclusion, Topical timolol solution is an effective and safe mode of treatment for fissures in patients with hand dermatitis, especially for those with a single fissure.

Ethical Clearance

Ethical clearance and approval of the study are ascertained by the author. All ethical issues and data collection followed the World Medical Association Declaration of Helsinki 2013 for ethical issues involving researchers involving humans, and informed consent was obtained from all patients. Data and privacy of patients were kept confidentially.

Funding

None, self-funded by the author.

REFERENCES

1. Hald M, Berg ND, Elberling J, Johansen JD. Medical consultations concerning the severity of hand eczema in the general population. *Br J Dermatol.* 2008; 158(4): 773-7.
2. Magina S, Barros MA, Ferreira JA, Mesquita-Guimaraes J. Atopy, nickel sensitivity, occupation, and clinical patterns in different types of hand dermatitis. *Am J Contact Dermat.* 2003; 14(2):63-8.
3. Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al. guidelines for diagnosis, prevention and treatment of hand eczema. *J Dtsch Dermatol Ges.* 2015; 13(1): 1-22.
4. Heede NG, Thyssen JP, Thuesen BH, Linnegerg A, Johansen JD. Predictive factors of self-reported hand eczema in adult Danes: a population-based cohort study with 5-year follow-up. *Br J Dermatol.* 2016; 175(2): 287-95.
5. Coenraads PJ. Hand eczema. *N Engl J Med.* 2012; 367(19):1829-1837.

Topical Timolol Eye Drop Solution for the Treatment of Fissures...

6. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of the epidermis: physiological and clinical significance. *J Invest Dermatol.* 2006; 126(9):1948-1965.
7. Cahn BA, Kaur R, Hirt PA, Tchanque-Fossuo C, Dahle SE, Kirsner RS, et al. Use Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of Recalcitrant Wounds of Varying Etiologies. *J Drugs Dermatol.* 2020; 19(12):1252-6.
8. Denda M, Fuziwara S, Inoue K. Beta-Adrenergic receptor antagonists accelerate skin recovery and reduce epidermal hyperplasia induced by barrier disruption. *J Invest Dermatol.* 2003; 121(1):142-148.
9. Pullar CE, Manabat-Hidalgo CG, Bolaji RS, Isseroff RR. β -adrenergic receptor modulation of wound repair. *Pharmacol Res.* 2008; 58(2):158-164.
10. Pullar CE, Isseroff RR. Cyclic AMP mediates keratinocyte directional migration in an electric field. *J Cell Sci.* 2005; 118(pt9):2023-2034.
11. Abdurrassol FA, Katof WM. Hand dermatitis among patients visited the dermatology clinic of Al-Sadder teaching hospital, Misan province. *Al-Mustansiriyah Journal of Science.* 2018; 29(1):44-48.
12. Mollerup A, Veien NK, Johansen JD. An analysis of gender differences in patients with hand eczema-everyday exposure, severity, and consequences. *Contact Dermatitis.* 2014; 71(1):44-48.
13. Power M. Topical timolol in chronic, recalcitrant hand eczema fissures. *J Am Acad Dermatol.* 2021; 84(3):e125-e6.
14. Braun LR, Lamel SA, Richmond NA, Krisner RS. Topical Timolol for Recalcitrant Wounds. *JAMA Dermatology.* 2013; 149(12):1400-2